Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer
Conditions
Keywords
Colorectal Neoplasms, Depression, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases, Palliative chemotherapy, Palliative care, Palliative treatment, Quality of life, Quality of life for relatives, Survival
Brief summary
In this trial, patients with cancer in the upper gastrointestinal canal who are going to receive first line palliative chemotherapy and patients with colorectal cancer who are going to receive second line palliative chemotherapy will be included. Participating patients will be randomized between early contact with a palliative care unit, or contact with a palliative care unit when needed. The objectives with the trial is to investigate if an early establishment with a palliative care unit will have a positive impact on the patients quality of life, this also applies for the nearest relative, survival, and if a difference in numbers of chemotherapy cycles can be detected.
Interventions
OTHERContact with palliative care unit.
Sponsors
Lund University Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with tumor in upper gastrointestinal canal, who is going to start treatment with first line palliative chemotherapy * Patients with colorectal cancer, who is going to start treatment with second line palliative chemotherapy * Signed written informed concent
Exclusion criteria
* Patients with neuroendocrine tumor * Patients with already ongoing chemotherapy * Patients with already established contact with palliative care unit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life, such as pain, anxiety. | At baseline, every 6th week until death (approximately 1 year). The patients relative will be followed similarly until patients death and then every 12th week for 1 year. | Evaluation will be performed by different quality of life forms sent to the patient every 6th week, and by telephone contact with a study nurse every 6th week until patients death. The same also applies for the patients nearest relative; quality of life forms will be sent every 12th week for additional 1 year. |
Secondary
| Measure | Time frame |
|---|---|
| Survival | Approximately 12 months. |
Other
| Measure | Time frame |
|---|---|
| Numbers of chemotherapy cycles | Approximately 12 months. |
Countries
Sweden
Outcome results
None listed